Braun Stacey Associates Inc. Sells 1,672 Shares of Lam Research Co. (NASDAQ:LRCX)

Braun Stacey Associates Inc. lowered its stake in Lam Research Co. (NASDAQ:LRCXFree Report) by 4.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,104 shares of the semiconductor company’s stock after selling 1,672 shares during the quarter. Lam Research makes up 1.3% of Braun Stacey Associates Inc.’s investment portfolio, making the stock its 17th largest position. Braun Stacey Associates Inc.’s holdings in Lam Research were worth $29,846,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Orion Capital Management LLC purchased a new stake in shares of Lam Research in the 3rd quarter valued at about $25,000. Bollard Group LLC raised its holdings in shares of Lam Research by 60.0% in the 2nd quarter. Bollard Group LLC now owns 40 shares of the semiconductor company’s stock valued at $26,000 after acquiring an additional 15 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in shares of Lam Research in the 3rd quarter valued at about $28,000. Resurgent Financial Advisors LLC purchased a new stake in shares of Lam Research in the 2nd quarter valued at about $29,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Lam Research in the 3rd quarter valued at about $30,000. Institutional investors own 84.61% of the company’s stock.

Insider Buying and Selling

In related news, Director Abhijit Y. Talwalkar sold 882 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total value of $857,330.46. Following the sale, the director now directly owns 10,541 shares of the company’s stock, valued at $10,246,168.23. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Abhijit Y. Talwalkar sold 882 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total value of $857,330.46. Following the sale, the director now directly owns 10,541 shares of the company’s stock, valued at $10,246,168.23. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Christina Corrreia sold 647 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total value of $628,903.41. Following the completion of the sale, the chief accounting officer now directly owns 5,541 shares in the company, valued at $5,386,018.23. The disclosure for this sale can be found here. Insiders have sold a total of 7,029 shares of company stock valued at $6,559,489 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Susquehanna raised their price target on Lam Research from $655.00 to $880.00 and gave the company a “neutral” rating in a report on Monday, January 29th. Needham & Company LLC raised their price objective on Lam Research from $800.00 to $900.00 and gave the company a “buy” rating in a report on Thursday, January 25th. The Goldman Sachs Group raised their price objective on Lam Research from $700.00 to $912.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Barclays raised their price objective on Lam Research from $750.00 to $825.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Finally, UBS Group raised their price objective on Lam Research from $885.00 to $1,130.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Eight research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $826.68.

Check Out Our Latest Stock Analysis on LRCX

Lam Research Price Performance

LRCX opened at $978.37 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.02 and a current ratio of 3.06. Lam Research Co. has a 52-week low of $480.45 and a 52-week high of $1,007.39. The stock has a market capitalization of $128.26 billion, a PE ratio of 37.83, a price-to-earnings-growth ratio of 3.44 and a beta of 1.51. The stock’s 50 day moving average price is $922.42 and its 200-day moving average price is $773.89.

Lam Research (NASDAQ:LRCXGet Free Report) last posted its earnings results on Wednesday, January 24th. The semiconductor company reported $7.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.06 by $0.46. Lam Research had a return on equity of 44.47% and a net margin of 24.15%. The firm had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same period in the previous year, the firm earned $10.71 earnings per share. The business’s revenue was down 28.8% compared to the same quarter last year. On average, equities research analysts predict that Lam Research Co. will post 28.88 EPS for the current year.

Lam Research Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 3rd. Stockholders of record on Wednesday, March 13th were paid a dividend of $2.00 per share. The ex-dividend date was Tuesday, March 12th. This represents a $8.00 annualized dividend and a dividend yield of 0.82%. Lam Research’s dividend payout ratio (DPR) is presently 30.94%.

About Lam Research

(Free Report)

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.

Featured Articles

Institutional Ownership by Quarter for Lam Research (NASDAQ:LRCX)

Receive News & Ratings for Lam Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lam Research and related companies with MarketBeat.com's FREE daily email newsletter.